Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a meglitinide antidiabetic. It has a different structure from the sulfonylureas, but a similar mechanism of action. It induces endogenous insulin secretion and can cause hypoglycemia.
Indicated in the treatment of type 2 diabetes.
Oral administration, before meals, two or three times a day.
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Its pharmacokinetic characteristics (very high plasma protein binding, moderately elevated molecular weight, large volume of distribution and short half life) make it very unlikely its excretion into breast milk in significant amounts.
Diet, exercise, and breastfeeding improve blood sugar levels.
See below the information of this related product: